Year: 2009
Type: article
Abstract: Contents Foreword 522 1. Antihyperglycaemic treatment of type 2 diabetes mellitus 523 1.1 Oral antidiabetic drugs 523 1.1.1 Non-β-cytotropic oral antidiabetic drugs 523 1.1.1.1 Metformin 523 1.1.1.2 Alpha-glucosidase inhibitors (acarbose, miglitol) 526 1.1.1.3 PPAR-γ-ligands (rosiglitazone, pioglitazone) 528 1.1.1.4 Combination therapy with non-β-cytotropic oral antidiabetic drugs 531 1.1.2 β-cytotropic medications: potassium channel blockers 531 1.1.2.1 Sulphonylureas 531 1.1.2.2 Sulphonylurea analogues (repaglinide, nateglinide) 533 1.1.2.3 Combination therapy with non-β-cytotropic oral antidiabetic drugs 534 1.1.3 DPP-4 inhibitors 534 1.2. Injectable therapies 538 1.2.1 Incretin mimetics (exenatide) 538 1.2.2 Insulin therapy 539 1.2.2.1 Indication 539 1.2.2 2 Blood glucose self-monitoring 540 1.2.2.3 Application 540 1.2.2.4 Insulin administration 540 1.2.2.5 Conventional therapy 540 1.2.2.6 Intensified conventional insulin therapy 541 1.2.2.7 Combination treatment with insulin and oral antidiabetic drugs 541 1.2.2.8 Side-effects of insulin therapy 542 2. Flowchart of antihyperglycaemic treatment of type 2 diabetes 543 2.1 Legend to flowchart 544 3. References 545 4. Appendix 1: Statement by the DDG regarding the results of the ACCORD and ADVANCE trials 553 1 Note: This updated version takes into account all evidence that was published prior to the end of 06/2008, as well as all new approvals/indications prior to the same date.
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W219049085
